Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms

Memorias do Instituto Oswaldo Cruz

Volumn 108, Issue 5, 2013, Pages 600-604

  Silva Moraes, Vanessa ^a,c   Couto, Flávia Fernanda Bubula ^a   Vasconcelos, Marah Mileib ^b   Araújo, Neusa ^a   Coelho, Paulo Marcos Zech ^a   Katz, Naftale ^a   Grenfell, Rafaella Fortini Queiroz ^a,b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSIDADE DE ITAÚNA   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antischistosomal drugs; Calcium channels antagonists; L type calcium channels; Nifedipine; Schistosoma mansoni

Indexed keywords

ANTISCHISTOSOMAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; PRAZIQUANTEL;

ANIMAL; ARTICLE; DRUG EFFECT; DRUG SENSITIVITY; MOUSE; SCHISTOSOMA MANSONI;

ANIMALS; CALCIUM CHANNEL BLOCKERS; MICE; NIFEDIPINE; PARASITIC SENSITIVITY TESTS; PRAZIQUANTEL; SCHISTOSOMA MANSONI; SCHISTOSOMICIDES;

EID: 84879659491     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/0074-0276108052013011     Document Type: Article

References (34)

1. Araújo N, de Mattos ACA, Coelho PMZ, Katz N 2008a. Association of oxamniquine praziquantel and clonazepam in experimental schistosomiasis mansoni. Mem Inst Oswaldo Cruz 103: 781-785.
2. Araújo N, de Mattos ACA, Sarvel AK, Coelho PMZ, Katz N 2008b. Oxamniquine, praziquantel and lovastatin association in the experimental schistosomiasis mansoni. Mem Inst Oswaldo Cruz 103: 450-454.
3. Beckmann S, Leutner S, Gouignard N, Dissous C, Grevelding CG 2012. Protein kinases as potential targets for novel anti-schistosomal strategies. Curr Pharm Des 18: 3579-3594.
4. Bonn D 2004. Schistosomiasis: a new target for calcium channel blockers? Lancet Infect Dis 4: 190.
5. Botros S, Bennett JL 2007. Praziquantel resistance. Expert Opin Drug Discov 2: 535-540.
6. Caffrey CR 2007. Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 11: 433-439.
7. Catterall WA 2000. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 16: 521-555.
8. Chitsulo L, Loverde P, Engels D 2004. Schistosomiasis. Nat Rev Microbiol 2: 12-13.
9. Coura JR, Amaral RS 2004. Epidemiological and control aspects of schistosomiasis in Brazilian endemic areas. Mem Inst Oswaldo Cruz 99 (Suppl. I): 13-19.
10. Day TA, Orr N, Bennett JL, Pax RA 1993. Voltage-gated currents in muscle cells of Schistosoma mansoni. Parasitology 106: 471-477.
11. Doenhoff MJ, Cioli D, Utzinger J 2008. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21: 659-667.
12. El-Lakkany NM, el-Din SHS, Sabra ANAA, Hammam OA 2011. Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni. Mem Inst Oswaldo Cruz 106: 814-822.
13. Fenwick A, Savioli L, Engels D, Robert Bergquist NR, Todd MH 2003. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19: 509-515.
14. Fenwick A, Webster JP 2006. Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis 19: 577-582.
15. Fetterer RH, Pax RA, Bennett JL 1980. Praziquantel, potassium and 2,4-dinitrophenol: analysis of their action on the musculature of Schistosoma mansoni. Eur J Pharmacol 64: 31-38.
16. Gönnert R, Andrews P 1977. Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd 52: 129-150.
17. Greenberg RM 2005a. Are Ca2+ channels targets of praziquantel action? Int J Parasitol 35: 1-9.
18. Greenberg RM 2005b. Ca2+ signalling, voltage-gated Ca2+ channels and praziquantel in flatworm neuromusculature. Parasitology 131: 97-108.
19. Hockerman GH, Peterson BZ, Johnson BD, Catterall WA 1997. Molecular determinants of drug binding and action on L-type calcium channel. Annu Rev Pharmacol Toxicol 37: 361-396.
20. Kohn AB, Anderson PAV, Roberts-Misterly JM, Greenberg RM 2001b. Schistosome calcium channel β subunits: unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J Biol Chem 276: 36873-36876.
21. 1 subunits from Schistosoma mansoni. Parasitology 123: 489-497.
22. Kohn AB, Roberts-Misterly JM, Anderson PAV, Khan N, Greenberg RM 2003. Specific sites in the beta interaction domain of a schistosome Ca2+ channel β subunit are key to its role in sensitivity to the antischistosomal drug praziquantel. Parasitology 127: 349-356.
23. Mendonça-Silva DL, Novozhilova E, Cobbett PJ, Silva CL, Noël F, Totten MI, Maule AG, Day TA 2006. Role of calcium influx through voltage-operated calcium channels and of calcium mobilization in the physiology of Schistosoma mansoni muscle contractions. Parasitology 133: 67-74.
24. Noël F, Cunha VMN, Silva CLM, Mendonça-Silva DL 2001. Control of calcium homeostasis in Schistosoma mansoni. Mem Inst Oswaldo Cruz 96 (Suppl.): 85-88.
25. Pax R, Bennett JL, Fetterer R 1978. A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch Pharmacol 304: 309-315.
26. Pica-Mattoccia L, Ruppel A, Xia CM, Cioli D 2007. Praziquantel and the benzodiazepine Ro 11-3128 do not compete for the same binding sites in schistosomes. Parasitology 135: 47-54.
27. Ramalho-Pinto FJ, Gazzinelli G, Howells RE, Mota-Santos TA, Figueiredo EA, Pellegrino J 1974. Schistosoma mansoni: defined system for stepwise transformation of cercaria to schistosomula in vitro. Exp Parasitol 36: 360-372.
28. Redman CA, Robertson A, Fallon PG 1996. Praziquantel: an urgent and exciting challenge. Parasitol Today 12: 14-20.
29. Salvador-Recatalà V, Schneider T, Greenberg RM 2008. Atypical properties of a conventional calcium channel beta subunit from the platyhelminth Schistosoma mansoni. BMC Physiol 8: 6.
30. Smithers SR, Terry RJ 1965. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of adult worms. Parasitology 55: 695-700.
31. Striessnig J, Grabner M, Mitterdorfer J, Hering S, Sinnegger MJ, Glossmann H 1998. Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol Sci 19: 108-115.
32. Triggle DJ 2007. Calcium channel antagonists: clinical uses-past, present and future. Biochem Pharmacol 74: 1-9.
33. Varon J 2008. Treatment of acute severe hypertension: current and newer agents. Drugs 68: 283-297.
34. Walter M, Kuris A 2003. Methods for the inhibition of egg production in trematodes. USA patent 6,514,963. 2003;B2.